Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
Open Access
- 10 August 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (8) , e0182715
Abstract
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval of a clinical trial application for Phase I clinical studies of ONCOS-102 (Ad5/3-D24-GM-CSF) for therapy of advanced cancers (NCT01598129). The study design, route of administration and dosage differs from the clinical protocol and in more detail, investigate bio-distribution and toxicological profile of ONCOS-102 treatment in animal model. The study was carried out in 300 hamsters divided into nine test groups–three bio-distribution groups and six groups for analysis of toxicity. Hamsters received ONCOS-102 by intracardial, intraperitoneal or subcutaneous injections. Additionally, one group was administered twice a week with intraperitoneal injections of Cyclophosphamide. The control animals were administered with NaCl solution without ONCOS-102 in the same volume and the same way. No adverse effects of repeated administration of ONCOS-102 including body weight, food consumption, hematology and clinical chemistry parameters, histopathology and bio-accumulation were observed in the course of 6-month administration and following 3- month recovery period. All obtained findings indicate the treatment clinically safe.Keywords
Funding Information
- Marie Curie Innovative Training Network (ITN), ADVance (FP7-290002)
This publication has 27 references indexed in Scilit:
- Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response, prominent infiltration of CD8+lymphocytes and Th1 type polarizationOncoImmunology, 2014
- Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic AdenovirusCancer Research, 2012
- Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapyBlood, 2012
- Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical DataMolecular Pharmaceutics, 2010
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSFMolecular Therapy, 2010
- Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumorsGene Therapy, 2010
- Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cellsThe Journal of Gene Medicine, 2009
- Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodiesGene Therapy, 2008
- GM‐CSF‐based cancer vaccinesImmunological Reviews, 2002
- How tumors escape immune destruction and what we can do about itCancer Immunology, Immunotherapy, 1999